40 research outputs found
Improved TransplantâFree Survival in Patients With Systemic SclerosisâAssociated Pulmonary Hypertension and Interstitial Lung Disease
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107488/1/art38623.pd
How should novelty be valued in science?
<p>Box plot analysis of serum concentrations of sRAGE (A), esRAGE (B), S100A9 (C) and HMGB1 (D) in patients with CTEPH (nâ=â26) and controls (nâ=â33). Independent Studentâs t-test was used to compare groups. <i>RAGE</i> receptor for advanced glycation endproducts, <i>sRAGE</i> soluble RAGE, <i>esRAGE</i> endogenous secretory RAGE, <i>S100A9</i> member of S100 family of Ca+ binding proteins, <i>HMGB1</i> high mobility group box1, <i>CTEPH</i> chronic thromboembolic pulmonary hypertension.</p
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase
Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?
Rapid Switch From Subcutaneous to Intravenous Treprostinil in Precapillary Pulmonary Hypertension by Pump Implantation
Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension. determinants and clinical impact
Over the past two decades randomized controlled trials of combination treatments for Pulmonary Arterial Hypertension (PAH) have demonstrated improvements of clinical status but only modest reductions in mean pulmonary arterial pressure (mPAP). Recent experiences with upfront combination treatments including parenteral prostacyclins have shown more substantial mPAP reductions, and have provided grounds for reconsiderations of treatment
The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is successfully treatable with pulmonary endarterectomy (PEA), balloon pulmonary angioplasty, and medical therapy. Registry to Evaluate Early and LongâTerm Pulmonary Arterial Hypertension Disease Management risk score (RRS) is able to predict longâterm outcome in inoperable patients or in patients with residual PH after surgery. We performed a post hoc analysis of RRS in patients who were enrolled in the CTREPH study (NCT01416636), a randomized, doubleâblind clinical trial comparing highâdose and lowâdose subcutaneous (SC) treprostinil in patients with severe CTEPH that was classified by an interdisciplinary CTEPH team as nonoperable, or as persistent or recurrent pulmonary hypertension after PEA. Baseline mean RRS was similar in both treatment groups (8.7 in highâdose arm vs. 8.6 in lowâdose arm), but mean RRS change from baseline to Week 24 was greater in the highâdose treprostinil group than in the lowâdose treprostinil group (â0.88 vs. â0.17). The difference in RRS change from baseline to Week 24 between high dose versus low dose was statistically significant with mean difference of â0.70 (95% confidence interval: â1.36 to â0.05, pâ=â0.0352), and was driven mainly by improvement of World Health Organization functional class and Nâterminal proâbrain natriuretic peptide concentration. SC treprostinil therapy administered in standard dose had positive effect on the risk profile measured by RRS in patients with inoperable or persistent/recurrent severe CTEPH. Although our study was limited by the small sample size and post hoc nature, assessment of risk profile is of great importance to this particular patient population with very poor prognosis